Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

News from ACC

    • 14 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    News from ACC. Pharmacoecon. Outcomes News 652, 4 (2012). https://doi.org/10.2165/00151234-201206520-00008

    Download citation

    Keywords

    • Atrial Fibrillation
    • Warfarin
    • Incremental Cost
    • Rivaroxaban
    • Apixaban